Vindecat de HCV cu med. generice. Cured with generics HCV drugs.
Thank you received: 1594
in some places on this planet some good things start to happen.
The Health Ministry from the Republic of Moldavia (neighboring country with Romania) announced recently it launched a national campaign to treat its patients having hepatitis B, C and/or D with generic drugs.
The number of patients to be treated with these drugs is 7 times higher as in the past. The drugs originate from Egypt and Bangladesh.
The fact that the drugs originate from Egypt and Bangladesh is mentioned here: e-medicina.md/bolnavii-de-ficat-primesc-...din-partea-statului/ (the text is available in Romanian language only .... but with Google translate one can get a good picture). At the end of the article is given also the amount of money that was used to purchase these drugs, which is incredibly low by compare with the branded medication.
Even though the number of patients which will be treated is lower than the total number of HCV patients from the Republic of Moldavia (thus the problem of HCV, HBV, etc is far from being solved), at least we can see that a country from Europe decided to use generic medication.
That's another piece of solid information to show to any doctor who (still) continues to "laugh" and discredit the generic medication...
In fiecare an HCV ucide peste 500000 oameni.Medicamentele generice pentru hepatita C functioneaza. Nu deveni statistica! Cauta pe Google “medicamente generice pentru hepatita C”.
HCV kills more than 500000 people every year. HCV generic drugs work. Don't become a statistic.
By sharing this Youtube video you might save someone’s life!
My TX: HEPCVIR-L[generic Harvoni]-India
The incidence and prevalence of patients with hepatitis C virus (HCV) infection is growing. However, the true worldwide incidence remains unknown due to heterogeneous registration and case definitions (European Centre for Desease Prevention Control, 2010). Overall, it is believed that the diagnosed global prevalence of HCV is approximately 2.0% (1.7–2.3%) for adults, which corresponds to approximately 104 (87–124) million persons world-wide (Table (Table1;1; McGowan et al., 2013; Mohd Hanafiah et al., 2013; European Association for the Study of the Liver, 2014; Hope et al., 2014; Wedemeyer et al., 2015). Others have suggested higher figures at 2.8% globally (Lemoine and Asia, 2014), leading to estimated prevalence rates of 150–184 million world-wide (Ramachandran et al., 2012; Mohd Hanafiah et al., 2013; Lemoine and Asia, 2014; Phelan and Cook, 2014; Barua et al., 2015; Cure et al., 2015; Norton, 2015; Fraser et al., 2016), with approximately 85% of patients living in low to middle income (LMIC) countries (Phelan and Cook, 2014). However, estimated figures for South Africa are lower at 0.1–1.7% (Fraser et al., 2016). In 2013, diagnosis rates vs. the estimated prevalence rates varied from 81% in Sweden and 43% in Belgium to just 16% in Turkey (Table (Table1;1; Dore et al., 2014; Wedemeyer et al., 2015).